
|Videos|August 7, 2021
Evaluating risuteganib for dry eye disease treatment
Author(s)David Hutton, Alex Delaney-Gesing
Advertisement
Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island (Garden City, NY), discusses highlights from his presentation of trial results analyzing risuteganib as a potential treatment for dry eye disease.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves NDA labeling supplement allowing re-administration of iDose TR
2
Opus Genetics launches phase 1/2 MERTK gene therapy trial
3
Dr. Mali’s top 5 predictions in ophthalmology for 2026
4
Cloudbreak Pharma completes FDA end-of-phase-2 meeting for CBT-004 in pinguecula
5



























